Evidence map›Paper›PMID 36624866›Full record

ArticleJournal of cellular and molecular immunology2022

Immunotherapy as a treatment to confront the ongoing opioid epidemic- A review.

Nachum Dafny

Open access · greenAbstract read
In one paragraph

Article in Journal of cellular and molecular immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Nachum DafnyUT Houston, McGovern Medical School, Department of Neurobiology and Anatomy, Houston Texas 77030 USA.
The University of Texas Health Science Center · US

Funding

How and Where Methylphenidate Exerts Effect in Adolescent and Adult BrainsR01DA027222 · NIDA · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DAFNY, NACHUM · 2009 to 2013
$1.5M
NIDA NIH HHS R01 DA027222
6 · The paper itself

Abstract

Substance use disorders continue to be major medical and social problems worldwide. The use of opiate has grown substantially over the past three decades reaching the dimensions of a global epidemic. Current drug treatments have many limitations: long treatment times, dependency on treatment medications, relapses after treatment, high costs of treatment, and non-adherence by affected persons. Most of the available drug treatments for opiate addiction belong to the opioid family. Some worry that the availability of the drugs may simply cause substituting one opioid medication for another. Immunotherapy has a great potential of becoming an additional therapeutic strategy in the treatment of addiction. Immunotherapy also prevents overdose of treatment drugs. This monograph reviews preclinical studies of immunotherapy and experiments using treatments with three different immunomodifiers that were able to significantly attenuate the severity of opioid withdrawal symptoms in morphine dependent animals. These immunotherapy treatments are short, and will prevent relapse of opioid dependency and toxicity.

Indexed as

AddictionCortisolCyclosporinInterferonMorphine

Identifiers

PMID36624866
PMCPMC9825804
OpenAlexW4288684860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.